Clinical Research Directory
Browse clinical research sites, groups, and studies.
Economic Analysis of Alliance A041202 CLL Study
Sponsor: Canadian Cancer Trials Group
Summary
The prospective cost-effectiveness (cost-utility) analysis from the perspective of the Canadian public healthcare system was completed in 2021. Health state utilities were collected using the EuroQOL EQ-5D instrument with Canadian tarrifs applied to calculate quality-adjusted life-years (QALYs). Costs were applied to resource utilization data (expressed in 20196 US dollars). We examined costs and outcomes (QALYs) associated with ibrutinib with rituximab (IR) and BR therapy.
Official title: Prospective Economic Analysis: A Randomized Phase III CLL Study of Bendamustine Plus Rituximab Versus Ibrutinib + Rituximab vs Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Key Details
Gender
All
Age Range
65 Years - Any
Study Type
OBSERVATIONAL
Enrollment
55
Start Date
2015-04-15
Completion Date
2026-04-09
Last Updated
2025-06-11
Healthy Volunteers
No
Conditions
Locations (15)
Tom Baker Cancer Centre
Calgary, Alberta, Canada
The Moncton Hospital
Moncton, New Brunswick, Canada
Health Sciences North
Greater Sudbury, Ontario, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Kingston Health Sciences Centre
Kingston, Ontario, Canada
London Regional Cancer Program
London, Ontario, Canada
Stronach Regional Health Centre at Southlake
Newmarket, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Humber River Hospital
Toronto, Ontario, Canada
Odette Cancer Centre Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
University Health Network Princess Margaret Cancer Centre
Toronto, Ontario, Canada
CSSS Champlain-Charles LeMoyne
Greenfield Park, Quebec, Canada
CHUM-CEntre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada
The Jewish General Hospital
Montreal, Quebec, Canada
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada